REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T.
Annals of Oncology 30(2) 259-265 Feb 2019 [Refereed]
Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, JASPAC 01 Study Group.
European journal of cancer (Oxford, England : 1990) 93 79-88 Apr 2018 [Refereed]
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan.
Liver international : official journal of the International Association for the Study of the Liver 38(3) 484-493 Mar 2018 [Refereed]
Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M
Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H
San Antonio Breast Cancer Symposium 2018 Dec 2018
Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, pha
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N
San Antonio Breast Cancer Symposium 2018 Dec 2018
The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy
Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M
International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference Sep 2018
REVERCE: randomized phase II study of regorafenib followed by cetuximab vs. reverse sequence for colorectal cancer
G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome
Hagiwara Y, Shinozaki T, Matsuyama Y
29th International Biometric Conference Jul 2018
REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis
Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K
European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018 Jun 2018
REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T
American Society of Clinical Oncology Annual Meeting 2018 Jun 2018
QOLの統計的評価：最近の成果から[Invited]
萩原康博，大橋靖雄
第89回QOL研究会 17 Sep 2017
SELECT BC のQOL、医療経済評価およびEQ-5Dについて: EQ-5Dへの有害事象の影響[Invited]
萩原康博
第11回CSP-HOR年会 1 Jul 2017
Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study.
Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H.
International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress 2 Nov 2016
Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H.
International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress 2 Nov 2016
Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial.
Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H.
International Society for Quality of Life Research 23rd Annual Conference 21 Oct 2016
Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.
Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H.
American Society for Clinical Oncology annual meeting 2016 Jun 2016
Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models
Hagiwara Y, Shinozaki T, Matsuyama Y
UK Causal Inference Meeting 4th annual meeting 12 Apr 2016
Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial
Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H
International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress 9 Nov 2015
Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models
Hagiwara Y
PeSeTo International Symposium on Public Health 2016 15 May 2015
